Peptide therapeutics occupy a coveted middle ground: they can hit targets undruggable by small molecules without the manufacturing complexity and intracellular access headaches of biologics. But that sweet spot collapses fast when a lead peptide vanishes from circulation in minutes. Metabolic instability—driven by a predictable but often under-interrogated cast of proteases, esterases, and oxidative enzymes—remains the leading cause of pharmacokinetic failure in peptide programs. Too many teams treat peptide metabolism as a black box, relying on generic hepatocyte stability assays that reveal a half-life problem without illuminating the specific amide bond or side chain that's breaking. In this Flash Talk, Bin Ma (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Genentech) opens that box. He walks through the dominant clearance pathways for therapeutic peptides, the tiered in vitro systems—plasma, S9 fraction, hepatocytes, and isolated enzyme panels—that map each metabolic soft spot, and the design rules that convert those insights into stability. You'll see real cases where single-point modifications, cyclization, or strategic N-methylation rescued molecules without sacrificing potency. For scientists who've watched a promising peptide vanish in a PK study, this is a pragmatic blueprint for doing metabolism right, early enough to matter.
Key Takeaways
- A defined workflow of orthogonal in vitro systems (plasma stability, tissue homogenates, hepatocytes, recombinant enzymes) that sequentially pinpoint the exact metabolic hot spots, rather than just confirming a liability exists.
- How to match specific metabolic pathways—hydrolysis by serine proteases, esterase cleavage, oxidative deamination—to the experimental conditions that best resolve them, including when to add co-factors like NADPH.
- Structural modification strategies with proven impact: N-methylation of solvent-exposed amides, macrocyclization to shield scissile bonds, and strategic side-chain replacement that preserves target binding while eliminating recognition by digestive proteases.
- Why enzyme phenotyping matters for peptides, and how to design a streamlined panel that reveals whether a single protease class (e.g., elastase, trypsin-like) dominates clearance, enabling focused chemistry rather than trial-and-error mutagenesis.
- The often-overlooked roles of formulation and non-structural tactics—including PEGylation, lipidization, and tight-binding excipients—as orthogonal levers when structural modification reaches its limit or threatens potency.
Who should watch: DMPK scientists and peptide medicinal chemists who design or triage peptide leads and need a rigorous, rather than anecdotal, metabolism de-risking cascade.
Why This Matters
The field is rapidly moving past the 'peptides are just unstable' cop-out and into a systematic, enzyme-by-enzyme DMPK discipline borrowed from small-molecule programs. This talk marks that shift: metabolism as a design parameter, not a post-hoc excuse.
